Rosai-Dorfman DiseaseSymptoms, Doctors, Treatments, Advances & More
Rosai-Dorfman Disease Overview
Learn About Rosai-Dorfman Disease
- Rosai-Dorfman disease
- RDD
- Rosaï-Dorfman disease
- SHML
- Sinus histiocytosis with massive lymphadenopathy
Rockefeller Outpatient Pavilion
Eli Diamond is an Oncologist practicing medicine in New York, New York. Dr. Diamond is rated as an Elite provider by MediFind in the treatment of Rosai-Dorfman Disease. He is also highly rated in 20 other conditions, according to our data. His clinical expertise encompasses Reticulohistiocytoma, Rosai-Dorfman Disease, Glioblastoma, Astrocytoma, and Awake Craniotomy. Dr. Diamond is currently accepting new patients.
MN - Cancer Hematology
Jithma Abeykoon is a Hematologist practicing medicine in Rochester, Minnesota. Dr. Abeykoon is rated as an Elite provider by MediFind in the treatment of Rosai-Dorfman Disease. He is also highly rated in 12 other conditions, according to our data. His clinical expertise encompasses Reticulohistiocytoma, Histiocytosis, Waldenstrom Macroglobulinemia, Tissue Biopsy, and Bone Marrow Transplant. Dr. Abeykoon is currently accepting new patients.
HealthPartners Frauenshuh Cancer Center
Gordon Ruan is an Oncologist and a Hematologist practicing medicine in S Saint Louis Park, Minnesota. Dr. Ruan is rated as an Elite provider by MediFind in the treatment of Rosai-Dorfman Disease. He is also highly rated in 5 other conditions, according to our data. His clinical expertise encompasses Reticulohistiocytoma, Histiocytosis, Rosai-Dorfman Disease, Non-Langerhans-Cell Histiocytosis, and Bone Marrow Aspiration. Dr. Ruan is board certified in American Board Of Internal Medicine-Medical Oncology, American Board Of Internal Medicine-Hematology, and American Board Of Internal Medicine. Dr. Ruan is currently accepting new patients.
Summary: The purpose of the study is to describe the burden of chronic health conditions, psychological dysfunction, chronic pain, healthcare utilization, worse health-related quality of life, overall mortality, and cause-specific mortality among individuals with histiocytic disorders
Summary: The purpose of this study is to determine the uptake of the imaging agent \[68Ga\]-pentixafor with PET/CT scans in people with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and non-Hodgkin lymphoma (NHL), or you have histiocytic neoplasms (Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD) and/or Rosai-Dorfman disease (RDD).
Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center

